Ligand Pharma (LGND) Tops Q4 EPS by 39c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $303.53 -1.39%
Revenue Growth %: -32.4%
Financial Fact:
Net income (loss):: 1.05M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -32.4%
Financial Fact:
Net income (loss):: 1.05M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.05, $0.39 better than the analyst estimate of $0.66. Revenue for the quarter came in at $28.1 million versus the consensus estimate of $25.65 million.
GUIDANCE:
Ligand Pharma sees FY2024 EPS of $4.25-$4.75, versus the consensus of $4.28. Ligand Pharma sees FY2024 revenue of $130-142 million, versus the consensus of $137.7 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Accenture shares fall on insider sales and analyst downgrade
- RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
